Metformin Milpharm

Metformin Hydrochloride, the active ingredient in Metformin Milpharm, is a Biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control. GNH USA supplies Metformin Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Milpharm belongs to the biguanide class and is used to manage disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve overall glycaemic control. - Prediabetes: reduces the risk of progression to overt diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome (PCOS): helps mitigate insulin resistance, which can improve ovulatory function and hormonal balance.

Metformin Milpharm may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Decreased appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: uncommon when used alone but possible with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas.

Before initiating Metformin Milpharm, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: evaluate liver enzymes; avoid in active liver disease. - Risk of lactic acidosis: consider contraindications such as hypoxia, sepsis, or alcohol abuse. - Elderly patients: start at lower doses and monitor tolerance closely. - Concomitant medications: review for drugs that may affect renal clearance or increase lactate production. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: enhances risk of lactic acidosis. - Rifampicin: reduces metformin exposure, potentially diminishing glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium levels. - NSAIDs: may impair renal function, increasing metformin levels. - Warfarin: occasional reports of altered INR; monitor coagulation status.